Clinical Characteristics and Management of Drug-Induced Lupus Caused by Tumor Necrosis Factor Inhibitors: A Comprehensive Review

Tumor necrosis factor (TNF) inhibitor (TNFi) therapy, commonly used to treat autoimmune conditions, such as ankylosing spondylitis (AS), rheumatoid arthritis, and psoriatic arthritis, has been associated with the development of drug-induced lupus (DIL). While the incidence of TNFi-induced DIL is rel...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2024-10, Vol.16 (10), p.e72522
Main Authors: Safaei, Seyedehtina, Kimiaei, Ali, Kasapoglu, Malik, Coşan, Fulya
Format: Article
Language:English
Subjects:
Antibodies
Arthritis
Case reports
Dyspnea
Fever
Immunoglobulins
Internal Medicine
Lupus
Pain
Patients
Pericarditis
Pleural effusion
Rheumatology
TNF inhibitors
Tumor necrosis factor-TNF
Ulcers
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumor necrosis factor (TNF) inhibitor (TNFi) therapy, commonly used to treat autoimmune conditions, such as ankylosing spondylitis (AS), rheumatoid arthritis, and psoriatic arthritis, has been associated with the development of drug-induced lupus (DIL). While the incidence of TNFi-induced DIL is relatively rare, it typically presents with mild symptoms and can often be managed with continued therapy or medication switches. This review explores the clinical characteristics, management strategies, and outcomes of TNFi-induced DIL through a comprehensive examination of cases reported in the literature. The findings suggest that most patients develop anti-double-stranded DNA (anti-dsDNA) positivity without severe clinical manifestations, and major organ involvement is uncommon. Treatment strategies vary; some patients can maintain TNFi therapy without disease exacerbation, while others require alternative treatments. Further research is needed to refine management protocols and improve patient outcomes.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.72522